Clinical Trial Update: Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004) [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetics update for MK-2060 in older participants with end-stage renal disease on hemodialysis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• MK-2060

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Dialysis, Kidney Failure, Chronic | Phase 1 | Status: COMPLETED | Results posted: 2024-06-06